NanoPass Technologies Ltd., a global leader in intradermal delivery solutions, will officially launch MicronJet™ 800 during IMCAS World 2026, taking place January 29 – 31, 2026, in Paris.
First human DNA vaccine First in class thermostable self-amplifying mRNA vaccine GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company engineering precision delivery systems that overcome challenges ...
The U.S. is now allowing fractional doses of the Jynneos monkeypox vaccine to be administered via an injection that delivers the dose between, rather than under, layers of skin — an effort that will ...
People who are at high risk for monkeypox can now get vaccinated for the virus via intradermal injection after the U.S. Food and Drug Administration authorized the technique. The FDA issued an ...
Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged The Food and Drug Administration (FDA) has granted emergency use ...
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced they received an ...
97% of healthcare workers preferred Tropis® ID for routine immunization. Vaccinators noted Tropis is easy to operate, resulted in less perceived child discomfort, and elicits a positive caregiver ...
PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference PharmaJet will deliver two presentations on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback